Clinical Trial: A Phase 1b, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07233239) titled 'A Phase 1b, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures' on Nov. 14.

Brief Summary: Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).

Study Start Date: Dec. 31

Study Type: INTERVENTIONAL

Condit...